Objective: To assess critically oritavancin, a second-generation lipoglycopeptide, for the treatment of Acute Bacterial Skin and Skin Structure Infections caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus.
The Medicines Company has announced results for its Phase III SOLO clinical trial program of oritavancin, which is under investigation...
The FDA has accepted the re filed application for oritavancin from The Medicines Company. The company is hoping to get...
Tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults (see sections 4.4 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
The European Commission has granted marketing authorization for Orbactiv (oritavancin), from The Medicines Co, for acute bacterial skin and skin...
The FDA has approved Kimyrsa (oritavancin), from Melinta Therapeutics, for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA).
The Medicines Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Melinta Therapeutics, LLC announced that the FDA has approved Kimyrsa (oritavancin) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA).